Device Endovascular Embolization

Lava Les (Liquid Embolic System)

Payments companies reported to CMS as associated with Lava Les (Liquid Embolic System). "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$803Kassociated payments (2023-2025)
956clinicians with associated payments
1company reporting

By year

2023 $37K
2024 $221K
2025 $545K

Payments reported as associated with Lava Les (Liquid Embolic System), per program year, as reported to CMS.

Who makes it

Specialties most often involved

Vascular & Interventional Radiology $646K
Diagnostic Radiology $127K
Vascular Surgery $13K
Medical Oncology $5,507
Physician Assistant $2,138
Surgery $1,318

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Lava Les (Liquid Embolic System)

These are the largest totals companies reported as associated with Lava Les (Liquid Embolic System). They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Gary Siskin Albany, NY Vascular & Interventional Radiology $132,018.61
Christopher Stark Albany, NY Vascular & Interventional Radiology $117,130.52
Bulent Arslan Chicago, IL Vascular & Interventional Radiology $71,339.02
Zachary Collins Kansas City, KS Diagnostic Radiology $41,736.63
Anoop Wattamwar Hackensack, NJ Diagnostic Radiology $34,327.54
Ziv Haskal Charlottesville, VA Vascular & Interventional Radiology $33,771.07
Ripal Gandhi Miami, FL Vascular & Interventional Radiology $28,825.78
Benjamin Ge Stanford, CA Vascular & Interventional Radiology $28,747.47
Guillermo Gonzalez-Araiza Saint Louis, MO Vascular & Interventional Radiology $25,883.95
Bhavraj Khalsa Orange, CA Vascular & Interventional Radiology $21,427.55

Prescribed Lava Les (Liquid Embolic System)?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.